The organizations granted WinSanTor an exclusive license to develop and commercialize small molecule antagonists of muscarinic receptor to treat peripheral neuropathy. The lead compound, WST-057, is in Phase I trials for the indication, with Phase II trials slated for 2017. WinSanTor declined to disclose financial details, and St. Boniface did not respond in time for publication. The universities did not respond to inquiries.
St. Boniface Hospital Albrechtsen Research Center, Winnipeg, Manitoba
University of California San Diego, La Jolla, Calif.
University of Manitoba, Winnipeg, Manitoba
WinSanTor Inc., San Diego, Calif.